What new areas will Moderna expand into?

Moderna plans to expand into three areas: oncology, autoimmune diseases, and cell therapies.

Does this mean Moderna will stop developing vaccines?

No, the expansion adds new areas to the mRNA platform, but vaccines remain a core part of the company's business.

What is mRNA technology?

mRNA is a technology that uses messenger RNA to instruct cells to produce specific proteins that stimulate immune responses or treat diseases.

Moderna Surges 33.5% on mRNA Platform Expansion into Oncology

Moderna (MRNA) shares surged 33.5% over the past week following the company's announcement of plans to expand its mRNA platform into new therapeutic areas including oncology, autoimmune diseases, and cell therapies, moving beyond vaccine development.

July 3, 2026

2 min read

Source: Zacks

Key Numbers

stock jump percent

33.5%

timeframe

past week

Moderna (MRNA) shares experienced a notable 33.5% surge over the past week, according to a report from Zacks. The rally follows the company's announcement of ambitious plans to expand its messenger RNA (mRNA) platform into new therapeutic areas beyond vaccines.

Expansion Details

Moderna outlined its new strategy focusing on three key areas:

Oncology: Developing immunotherapies targeting cancer cells.
Autoimmune Diseases: Designing treatments that modulate the immune system.
Cell Therapies: Producing therapeutic proteins inside cells to treat rare diseases.

Context

The move comes as Moderna seeks to diversify its revenue streams following declining demand for COVID-19 vaccines. The platform, proven effective in vaccine development, shows promising potential in other therapeutic areas, potentially opening up multibillion-dollar markets.

What This Means for Investors

While the expansion is still in early stages, the announcement boosts investor confidence in Moderna's innovation capabilities and business diversification. However, clinical and regulatory developments should be closely monitored to assess the commercial viability of these projects.

Frequently Asked Questions

The stock rose after the company announced plans to expand its mRNA platform into oncology, autoimmune diseases, and cell therapies.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.